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Effects of selected bioactive food
compounds on human white adipocyte
function
Christel Björk1,5*, Uta Wilhelm1, Susanne Mandrup2, Bjørk Ditlev Larsen2, Alessandra Bordoni3, Per Hedén4,
Mikael Rydén1, Peter Arner1 and Jurga Laurencikiene1
Abstract
Background: Previous studies suggest that intake of specific bioactive compounds may have beneficial clinical
effects on adipose tissue partly due to their anti-inflammatory and insulin-sensitizing properties. With the overall
aim to contribute to better understanding of the mechanisms of selected bioactive nutrients on fat metabolism, we
investigated their role on human white adipocyte function.
Methods: The influence of the omega-3-fatty acid docosahexaenoic acid (DHA), the anthocyanin (AC) cyanidin-3-
glucoside and its metabolite protocatechuic acid, and the beta-glucan metabolite propionic acid (PI) on adipokine
secretion, fatty acid metabolism (lipolysis/lipogenesis) and adipocyte differentiation (lipid accumulation) was studied
in human fat cells differentiated in vitro. To investigate possible synergistic, additive or antagonistic effects, DHA
was also combined with AC or PI.
Results: Each compound, alone or together with DHA, suppressed basal adipocyte lipolysis compared to
control treated cells. DHA alone attenuated the secretion of pro-inflammatory adipokines such as chemerin,
interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1/CCL2), whereas AC suppressed only the
latter two. Treatment with PI decreased IL-6, tumour necrosis factor alpha (TNFα) and adiponectin secretion. A
combination of DHA and AC decreased TNFα secretion and increased insulin-stimulated lipogenesis. No effect
was found on adipocyte differentiation. At the selected concentrations, none of the compounds was found to
be cytotoxic.
Conclusion: The studied bioactive food compounds or their metabolites have beneficial effects in human
primary fat cells measured as decreased basal lipolytic activity and secretion of inflammatory markers. A minor
effect was also observed on insulin-stimulated glucose uptake albeit only with the combination of DHA and
AC. Taken together, our results may link the reported health benefits of the selected bioactives on metabolic
disorders such as insulin resistance, hypertension and dyslipidemia to effects on white adipocytes.
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Background
It is well established that white adipose tissue (WAT)
metabolism and inflammatory status affect whole body
homeostasis [1]. The major role of WAT is to store and
release energy. Storing energy in the form of triacylglyc-
erol (TAG) in adipocytes through lipogenesis has been
shown to regulate systemic insulin sensitivity [2, 3]. Hy-
drolysis of TAGs into non-esterified fatty acids and gly-
cerol is a tightly controlled enzymatic process denoted
lipolysis. Basal (spontaneous) lipolytic activity is in-
creased in obesity and may attenuate insulin sensitivity
through increased delivery of FAs to skeletal muscle
(reviewed in [4]). Another important aspect of WAT
function is the secretion of a class of proteins called adi-
pokines, several with pro- or anti-inflammatory proper-
ties (see [1] for review). An elevated release of monocyte
chemoattractant protein-1 (MCP-1/ CCL2) produced by
adipocytes [5, 6] recruits macrophages, which in turn
promote a chronic low grade inflammation in WAT [7].
Release of other pro-inflammatory adipokines, such as
interleukin-6 (IL-6), tumour necrosis factor-alpha
(TNFα) and chemerin may also contribute to metabolic
disorders such as insulin resistance, dyslipidemia, hyper-
tension and cardiovascular disease [8–10], which are
associated with the development of the metabolic syn-
drome [11]. The anti-inflammatory adipokine adiponec-
tin has on the other hand been shown to correlate
negatively with BMI (Body mass index, defined as body
weight in kilograms divided by height in meters squared)
and positively with insulin sensitivity [12, 13] and its
high levels are associated with a lower risk for develop-
ing type 2 diabetes [14].
Diet composition can affect the metabolic and endo-
crine function of WAT as well as overall energy balance
[15]. Certain diets that provide high amounts of bio-
active components may have beneficial clinical effects
partly due to their anti-inflammatory effects on adipose
tissue (see [15, 16] for reviews). A number of natural
bioactive compounds that can be added to the food or
their metabolic derivatives have been tested for their ac-
tion on fat cells. The omega-3 long-chain polyunsatur-
ated fatty acid docosahexaenoic acid (DHA) can be
synthesized from the essential alpha-linoleic acid. How-
ever, minor (clinically insufficient) amounts are synthe-
sized endogenously and significant levels can only be
provided exogenously through intake of fish and fish oil.
A previous study using human adipocytes and WAT sug-
gested an anti-inflammatory effect of DHA via decreased
levels of IL-6 and MCP-1 [17]. In vitro studies regarding
the regulation of DHA on adiponectin production have
been performed both in mouse and human adipocytes,
however the results are conflicting [18–20]. Anthocya-
nins (AC) are naturally occurring polyphenol com-
pounds present in blue or purple berries, fruit and
vegetables [21]. Cyanidin-3-glucoside (C3G) is the most
studied anthocyanin that together with its main metab-
olite protocatechuic acid (PCA) has been shown to be
protective against insulin resistance in both human adi-
pocytes in vitro [22, 23] and an in vivo diabetic mouse
model [24, 25] as well as having anti-inflammatory prop-
erties [22, 24–26]. Beta-glucan (BG) is a soluble dietary
fiber present in oats and barley. However, BG is not
absorbed in vivo, but its metabolism by the gut micro-
biota results in increased production an uptake of short-
chain fatty acids (SCFA), such as propionic acid (PI),
which has been shown to regulate adipokine production
and enhance lipogenesis and glucose uptake in isolated
human WAT [27, 28].
Most studies investigating effects of these compounds
have been conducted in murine adipose cell lines or in
vivo mouse or rat models [29–32], which display a num-
ber of species-specific differences concerning adipose
tissue function [33–35]. Furthermore, in previous studies
the compounds have been tested individually and the ex-
perimental conditions as well as fat cell model systems
have varied markedly. In addition, in most cases a single
metabolic or inflammatory aspect of adipocyte function
has been investigated.
As a part of the pan-European study PATHWAY-27
(http://www.pathway27.eu/) with the overall aim to con-
tribute to better understanding of the mechanisms of
bioactive nutrients on metabolism in different food-
environments and help to develop health-promoting
food for the growing demand of the health-conscious
consumer, we have investigated the role of selected bio-
actives or their main metabolites on adipocyte pheno-
types linked to obesity and the metabolic syndrome.
Methods
Cell cultures of primary human adipocytes
Primary human pre-adipocytes for in vitro differenti-
ation from 22 female subjects and 2 male subjects be-
tween 26-65 (mean 42) years of age with a BMI ranging
from 21-31 kg/m2 (mean 25) were isolated from the
stromal vascular fraction of subcutaneous WAT, which
was obtained as a waste product from cosmetic liposuc-
tion. Isolation, culture and differentiation into adipocytes
were performed as previously described [36]. The sub-
jects were healthy according to self-report and not
selected for age, sex or BMI. Briefly, intact pieces of adi-
pose tissue were cut into 3-4 mm pieces and digested
with collagenase for 90 min at 37 °C, whereas material
obtained from liposuctions was digested with collage-
nase for 45 min at 37 °C. Thereafter the cell suspension
was filtered, centrifuged at 200 × g for 10 min. The
remaining pre-adipocytes and mesenchymal stem cells
in the stromal vascular fraction were then suspended in
erythrocyte lysis buffer for 10 min and centrifuged. The
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supernatant was discarded, the cells suspended in prolif-
eration medium containing Dulbecco’s Modified Eagle
Medium (DMEM)/F12 (Biochrome AG, Berlin, Germany/
Gibco, Life Technologies) supplemented with 10 % fetal
bovine serum (Gibco, Life Technologies) and 2 %
Pen-Strep (Gibco, Life Technologies) and subsequently
filtered through a 70 μm cell strainer (BD BioSciences,
Durham, NC) .
To study the effects of bioactives on fat cell metabol-
ism and adipokine secretion, the cells were plated in
proliferation medium at a density of 115 000 to 120 000
cells/well in 24-well plates. After 24 h, the medium was
changed to DMEM/F12 supplemented with 15 mM
HEPES (Gibco, Life Technologies), 100 μg/ml penicillin-
streptomycin (Gibco, Life Technologies), 66 nM human
insulin, 1 nM triiodo-L-thyronine, 10 μg/ml human
transferrin, 33 μM biotin, 17 μM panthothenate, 100 nM
cortisol (all from Sigma St. Louis, MO), 1.25 μg/ml
amphotericin B (Gibco, Life Technologies) and 10 μM
rosiglitazone (BRL49653) (GlaxoSmithKline, Durham,
UK) to induce differentiation. Rosiglitazone was included
during the first 3-4 days and then removed from the
differentiation medium. Medium was changed every 2-3
days and the cells were kept until full differentiation (12-
14 days). Forty-eight hours before full differentiation, the
compounds were added in adipogenic medium.
To investigate the effects of bioactives on lipid accu-
mulation, 20 000 cells/well were seeded in 96-well
plates. Medium was supplemented with the compounds
after 6 days in differentiation medium and treatment
was performed for 6 days until day 12 of differentiation.
Adipose tissue stromal vascular fraction, which we use
to in vitro differentiate adipocytes, contains various cell
types including immune cells. At day 6 of differentiation,
immune cells are almost entirely washed away and ab-
sent and this is the earliest time point in differentiation,
where effects unspecific for adipocytes could be ex-
cluded. Each experiment was repeated in cells isolated
separately from at least three individuals in duplicates
(lipid accumulation and lipogenesis) or quadruplicates
(lipolysis and adipokine secretion). Cytotoxicity of com-
pounds was measured for all treatment conditions. The
grade of differentiation was determined under the
microscope and cells with differentiation grade below
80 % were discarded. The study was approved by the
Ethics Committee at Karolinska Institutet (Sweden). All
subjects were informed about this study and provided
their written informed consent.
Treatment with bioactive compounds
The cells were treated with DHA (D8768, sodium salt,
Sigma, St. Louis, MO), C3G (1201-1, chloride salt,
Polyphenols Laboratories AS, Sandes, Norway) together
with its metabolite PCA (03930590, Sigma) or the BG
metabolite PI (P1880, sodium salt, Sigma). To study pos-
sible synergistic, additive or antagonistic effects with
DHA, the bioactive compound was also studied in com-
bination with AC or PI. Compound concentrations were
based on relevant literature [27, 37] and unpublished
treatment optimizations in the human Simpson-Golabi-
Behmel syndrome (SGBS) pre-adipocyte cell line or in a
hepatocyte cell line by collaborators in the PATHWAY-
27 consortium. DHA was coupled to bovine serum albu-
min (BSA; A6003, Fraction V, Sigma) in a 4:1 ratio.
Firstly, BSA was dissolved in 150 mM NaCl in a 37 °C
water bath and filtered via a sterile 0.2 μm polypropylene
membrane (VWR International, USA). Shortly after,
DHA was dissolved in water and heated to 70 °C in a
water bath. The coupling was performed through mixing
both heated solutions and stirring for 1 h at 37 °C
(pH 7.4). The final DHA concentration in the cell culture
medium was 0.5-60 μM. C3G was dissolved in phosphate-
buffered saline (PBS, Gibco, Life Technologies) whereas
its main metabolite PCA was diluted in 50 % v/v solu-
tion of ethanol in water. According to agreements
within the PATHWAY-27 consortium, C3G and PCA
were added together to represent AC in a final con-
centration of 130 nM and 13 μM, respectively. PI
(P1880, sodium salt, Sigma) was dissolved in 50 % v/v
solution of ethanol in water and added to the cells at
a final concentration of 100 μM. Corresponding con-
centrations of BSA and EtOH were added the control
samples. As higher concentrations of BSA has been re-
ported to have stimulatory effect on inflammatory cyto-
kine secretion [38], we have performed control
experiments comparing BSA and EtOH (at concentra-
tions used in all our treatments) to untreated cells.
Such treatment did not affect release of IL-6 and gly-
cerol (Additional file 1: Figure S1).
Cytotoxicity measured as lactate dehydrogenase (LDH)
activity in conditioned medium
Medium from bioactive treated cells was collected when
full differentiation was reached. LDH activity, as a meas-
ure of damaged cells, was quantified according to the
manufacturer’s instructions (Cat. No. 11 644 793 001,
Roche Diagnostics GmbH, Mannheim, Germany).
Lipolysis assay
Conditioned medium was collected after 48 h of treat-
ment with the bioactive compounds. Basal lipolytic
activity was measured as glycerol release with a bio-
luminescence method using Free Glycerol determination
kit from Sigma (FG100) in combination with the fluores-
cence probe Amplex ultra red reagent (Cat. No. A36006,
Molecular Probes, Life Technologies) [39, 40]. Glycerol
release was normalized to protein concentration in each
cell culture well.
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Lipogenesis
Determination of basal and insulin-stimulated glucose
incorporation into lipids was made when cells reached
full differentiation that is after 48 h of bioactive treat-
ment. Cells were initially washed twice with insulin- and
glucose free DMEM (BioChromeAG) and incubated in
DMEM containing 1 μM glucose. After 3 h, 3-3H glu-
cose (37 MBq/ml; Perkin Elmer-Cetus, Norwalk, CT) di-
luted 1:1000 in DMEM containing 1 μM glucose with
was added. For stimulated lipogenesis, insulin was added
to a final concentration of 100 nM. After 2 h of incuba-
tion, the cells were washed three times with 4 °C PBS
and thereafter lysed in aqueous 0.1 % SDS (sodium do-
decyl sulfate, Sigma) solution. An aliquot was saved for
protein determination and the rest of the lysate was
transferred to scintillation tubes. Toluene scintillation li-
quid (toluene with 5 g/l 2,5-diphenyloxazol and 0.3 g/l
1,4-bis (4-methyl-5-phemyl-2-oxazolyl)-benzene; Sigma-
Aldrich) was added and the samples were incubated
overnight to extract the lipids. Glucose incorporation
into lipids as a proxy of lipogenesis was quantified as
3-3H counts per minute (CPM) using a LS 6500
Multi-Purpose scintillation counter (Beckman, USA).
Adipokine quantification by enzyme-linked immunosorbent
assay (ELISA)
To quantify the secretion of pro- (IL-6, MCP-1, che-
merin, and TNFα) and anti-inflammatory (adiponectin)
adipokines, cells were treated with bioactive compounds
for 48 h and conditioned medium was collected for
adipokine quantification by ELISA according to the
manufacturer’s instructions. The samples were diluted
5-60 fold for IL-6 detection (Quantikine ELISA Human
IL-6 Immunoassay; R&D Systems, Minneapolis, MN,
Intra-assay precision: CV <5 %, Inter-assay precision:
CV <4 %), 3-10 fold for MCP-1 (Quantikine ELISA
Human CCL3/MCP-1 Immunoassay; R&D Systems,
Intra- and Inter-assay precision: CV <6 %) and 2-10
fold for chemerin (Quantikine ELISA Human Chemerin
Immunoassay; R&D Systems, Intra-assay precision:
CV ≤3 %, Inter-assay precision: CV <6 %) to match
the standard curve. Adiponectin (Mercodia Adiponectin
ELISA; Mercodia AB, Uppsala, Sweden, Intra-assay preci-
sion: CV <5 %, Inter-assay precision: CV <8 %) and TNFα
(Quantiglo ELISA Human TNFα Immunoassay; R&D
Systems, Intra-assay precision: CV <6 %, Inter-assay preci-
sion: CV <9 %) secretion were measured in undiluted
samples. Levels of TNFα were detectable in adipocyte cul-
tures treated with AC from only two subjects.
Protein quantification
Protein amount was quantified in SDS lysates from the
lipogenesis experiments using Pierce™ BCA Protein
Assay Kit (Cat. No. 23225 Pierce, Rockford, IL) according
to the manufacturer’s instructions. The protein concentra-
tion for each well was used to normalize glucose incorpor-
ation into lipids as well as glycerol release, LDH activity
and adipokine secretion for cell amount.
Neutral lipid and DNA staining
The cells were differentiated in 96-well plates and
treated with the bioactive compounds for 6 days before
full differentiation. Medium supplemented with the
compounds was added to the cell cultures every second
day. Before staining, the cells were washed with PBS and
fixed with 4 % paraformaldehyde solution (PFA) contain-
ing 0.123 M NaH2PO4xH2O, 0.1 M NaOH and 0.03 M
glucose for 10 min at room temperature. Fixed cells
were washed with PBS and stained with Hoechst 33342
(2 μg/ml; staining cell nuclei, Cat. No. H3570, Molecular
probes) and Bodipy 493/503 (0.2 μg/ml; staining neutral
lipids, Cat. No. D-3922, Molecular probes) diluted in
PBS for 20 min at room temperature. After washing with
PBS, accumulation of intracellular lipid droplets and cell
number (stained nuclei) were quantified with Acumen
eX3 imager (TTP Labtech, Hertfordshire, UK). Bodipy
lipid droplet fluorescence was normalized to the amount
of nuclei in each well (Hoechst).
Statistical analysis
The impact of DHA, AC and PI on cytotoxicity, lipid ac-
cumulation, adipokine secretion and metabolic out-
comes (lipolysis/lipogenesis) was compared to control
cells without bioactives. If statistical significance was
reached, the effect was also compared with the other
bioactives having significant outcomes. Additionally, to
investigate possible combinatorial (synergistic, additive
or antagonistic) effects of DHA exposure, the impact of
DHA alone was compared to that obtained in combin-
ation with AC or PI. If a difference was found, AC and
PI exposure alone was compared to the effect of the re-
spective bioactive in combination with DHA. The data
was tested for normal distribution with the Shapiro-
Wilk test. If the criteria for normal distribution were
fulfilled, one-way analysis of variance (ANOVA) with
subsequent Tukey’s HSD post-hoc test was utilized.
When the criteria for normal distribution were not
achieved, the non-parametric Kruskal-Wallis and Mann-
Whitney pair-wise comparison tests were used. The
level of statistical significance was set as 0.05 with
*p < 0.05, **p < 0.01 and ***p < 0.001. Bars are shown
as mean ± standard deviation.
Results
Titration of the in vitro conditions for DHA treatment of
primary human adipocytes
DHA concentrations that have been used in other fat
cell systems (10-60 μM) [18–20, 41] as well as in
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optimizations by PATHWAY-27 collaborators in SGBS
cells, induced LDH activity in conditioned media
(after 6 days of stimulation) and increased IL-6 secre-
tion (after 48 h of stimulation), indicating both cyto-
toxic and pro-inflammatory effects (Additional file 2:
Figure S2). These findings are difficult to reconcile
with the reported physiological effects of omega-3-
fatty acids in vivo [42]. Consequently, the DHA con-
centration was titrated down and 0.5 μM was selected
as the highest non-toxic DHA concentration in our
primary culture system.
Decreased basal adipocyte lipolysis after treatment with
bioactive compounds
Glycerol release was significantly decreased after all
treatments when compared to control, with the excep-
tion of AC (p = 0.056) (Fig. 1). Treatment with PI had
the strongest attenuating effect on glycerol release com-
pared to control-treated cells which was stronger than
that of DHA (p = 0.009). None of the compounds in-
duced cytotoxicity at the selected concentrations, but ra-
ther reduced LDH activity in cell cultures after 48 h of
treatment (Additional file 3: Figure S3), except for AC in
combination with DHA (p = 0.321, due to a large inter-
individual variation of the response). LDH activity
remained unaltered up after 6 days of treatment with the
bioactive compounds.
Combined treatment with DHA and AC increased insulin-
stimulated adipocyte lipogenesis
To determine the effects of the bioactive compounds or
their metabolites on insulin-stimulated lipogenesis, rela-
tive glucose incorporation into lipids was measured in the
in vitro differentiated primary adipocytes. Insulin induced
lipogenesis in the control and all treatment conditions
(Fig. 2). No effect on insulin-stimulated response was
found after treatment with any of the compounds alone.
However, combined treatment with DHA and AC in-
creased insulin-stimulated glucose uptake compared to
the control.
Bioactives alter secretion of pro-inflammatory adipokines
and adiponectin
To investigate the effect of the bioactive compounds or
their metabolites on a panel of the most important pro-
(IL-6, MCP-1, TNFα, chemerin) and anti-inflammatory
(adiponectin) adipokines, conditioned media from the
adipose cells were collected after 48 h of treatment
and secretion was measured by ELISA. IL-6, MCP1
and chemerin secretion were suppressed by DHA
(Fig. 3a, b and e). The effect of DHA on MCP-1 and
chemerin secretion was also statistically significant in
combination with PI (Fig. 3b and e). Additionally,
DHA combined with PI impeded TNFα secretion, a
Fig. 1 Decreased basal adipocyte lipolysis after treatment with
bioactive compounds or metabolites. Glycerol release after 48 h of
treatment with 0.5 μM docosahexaenoic acid (DHA), anthocyanin (AC),
that is 130 nM cyanidin-3-glucoside (C3G) and 13 μM protocatechuic
acid (PCA), and 100 μM propionate (PI), relative to control, measured in
conditioned medium from human in vitro differentiated adipocytes.
Control, n = 9; 0.5 μM DHA, n = 6; AC alone and with DHA, n = 3;
100 μM PI alone and with DHA, n = 4 biological/independent
experiments in quadruplicates. Normalized data is adjusted for
protein amount and presented as means +/- standard deviation.
*p < 0.05, **p < 0.01 and ***p < 0.001 versus control. Statistical
significance was determined by one-way ANOVA with Tukey’s
multiple comparisons post hoc test
Fig. 2 Combined treatment with DHA and AC increased insulin-
stimulated adipocyte lipogenesis. Basal and insulin-stimulated lipo-
genesis measured in cell lysates after 48 h of treatment with bio-
active compounds. Control, n = 8; 0.5 μM DHA, n = 6; AC alone and
with DHA, n = 3; 100 μM PI alone, n = 3 and with DHA, n = 4 bio-
logical/independent experiments in duplicates. Glucose incorporation
into lipids (3-3H counts per minute) is normalized for protein concen-
tration in the cell lysates for each well. Normalized data is presented as
means +/- standard deviation. *p < 0.05, **p < 0.01 and ***p < 0.001
counted against basal control with the same bioactive treatment
or insulin-stimulated control compared with insulin-stimulated
bioactive treated cells. Statistical significance was determined by
the non-parametric Kruskal-Wallis test with subsequent Mann-Whitney
multiple comparisons post hoc test
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result that was also obtained with PI alone (Fig. 3d). PI
was the only compound that had an effect on adiponectin,
contributing to a slightly decreased secretion (Fig. 3c). As
the other two compounds, PI suppressed IL-6 secretion
(Fig. 3a). AC alone attenuated IL-6 and MCP-1 secretion
and in combination with DHA, demonstrated a sup-
pressed secretion of TNFα (Fig. 3a, b and d).
No effects of bioactives on adipocyte differentiation
To measure possible effect of bioactives on adipocyte
differentiation and lipid accumulation, cells were treated
for 6 days and lipid content was measured by Bodipy
staining and normalized per cell based on DNA staining
by Hoechst (Fig. 4a). No effects were found of the
selected compounds on lipid accumulation after 6 days
of treatment (Fig. 4b).
Discussion
Using a systematic assessment of the effects of specific
bioactive food compounds and their metabolites in
human white fat cells, we found beneficial effects of
DHA, AC and PI, either alone or in combination with
DHA, on fat cell metabolism and inflammatory pheno-
type in vitro. The in vitro differentiated non-expanded
human primary adipocytes used herein, is the closest
model to human fat cells in vivo and enables longer
treatments with the compounds. Treatments in in vitro
systems always raise a question on the physiological con-
centrations of the stimuli applied and relevance of the
resulting effects for the in vivo situation. We utilized
lower concentrations of DHA than that measured in
blood [43, 44]. However, higher concentrations of DHA
induced cytotoxicity and pro-inflammatory response as
in previous studies [20, 45]. Since the formation of react-
ive oxygen species (ROS) correlates with the number of
double bonds in a polyunsaturated fatty acid, DHA is
highly susceptible to spontaneous oxidation. ROS acti-
vate surface receptors such as Toll-like receptors which
can trigger a downstream signalling cascade, leading to
activation of the NF-kappaB pathway, which then turn
Fig. 3 Bioactives or metabolites alter secretion of pro-inflammatory adipokines and adiponectin. Secretion of adipokines; interleukin-6 (IL-6) (a),
monocyte chemoattractant protein-1 (MCP-1) (b), adiponectin (c), tumour necrosis factor α (TNFα) (d) and chemerin (e); after 48 h of treatment
with bioactive compounds relative to control in conditioned media. Control, n = 6-9; 0.5 μM DHA, n = 3-6; AC alone and with DHA, n = 3; 100 μM
PI alone and with DHA, n = 3-4 in biological/independent experiments in quadruplicates, with the exception of TNFα where n = 2-6 due to levels
below minimum detectable dose in four subjects. Normalized data is adjusted for protein amount and presented as means +/- standard
deviation. *p < 0.05, **p < 0.01 and ***p < 0.001 versus control. Statistical significance was obtained by one-way ANOVA with Tukey’s
multiple comparisons post hoc test
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on the transcription of many pro-inflammatory genes
[46, 47]. In the support of this hypothesis, ascorbic acid
suppressed the pro-inflammatory effect in our primary
human adipocyte culture (data not shown). Furthermore,
total plasma levels of DHA should not be interpreted as
equivalent to local extracellular or intracellular concen-
trations. To the best of our knowledge, there are no
studies that have measured the actual concentration of
DHA in adipose tissue. However, we cannot exclude that
in the in vivo environment higher concentrations of
DHA would be needed for optimal effects. Additionally,
none of the other compounds displayed cytotoxicity in
our cell cultures and the concentrations used for PI and
AC were close to those reported in human blood [48, 49].
All three compounds suppressed basal adipocyte
lipolysis, where the effect of PI was slightly more
pronounced compared with DHA and AC. This could at
least in part be due to a fact that PI also significantly at-
tenuated the secretion of TNFα, a potent inducer of adi-
pocyte lipolysis [33]. Our finding corroborate results
from a study where healthy subjects were supplemented
for 4 weeks with non-digestible starch and demonstrated
decreased adipose tissue glycerol release as well as
reduction in the activity of hormone-sensitive lipase, the
rate-limiting enzyme responsible for mobilization of
stored TAGs [49]. We therefore suggest that PI might
exert its effects at least in part by altering adipocyte lipid
metabolism via indirect (through TNFα) or direct mech-
anisms. In fact, although the latter mechanism has not
been not studied in humans, in mice PI has been sug-
gested to interact with the G-protein coupled receptor
43 [29], a receptor that is suggested to be involved in
regulating inflammatory responses, and is also expressed
in human WAT [28]. Regarding ACs, an anti-lipolytic ef-
fect has been observed in 3T3-L1 adipocytes during
hyperglycemia, where C3G regulated FoxO1-mediated
transcription of adipose triglyceride lipase resulting in
decreased expression of this lipolytic enzyme [50].
Whether or not this also implies for human adipocytes
remains to be investigated. The mechanism of lipolysis
reduction by DHA is not known. However, no additive
effects between compounds were observed, suggesting
that they might act via similar mechanisms.
The synergistic effect between DHA and AC on
insulin-induced lipogenesis might partly be explained by
the activation of PPARγ by AC, which results in in-
creased expression and translocation of GLUT4 [22]. In
addition, the effect on lipogenesis could result from de-
creased TNFα secretion caused by combined DHA and
AC treatment. We and others have shown that TNFα
addition in cultures of primary human adipocytes causes
insulin resistance [51, 52]. However, a combination of PI
and DHA also lowered TNFα secretion but did not
affect lipogenesis, which may suggest different mecha-
nisms of action.
Earlier studies both in mice WAT and human adipo-
cytes have shown suppression of pro-inflammatory cyto-
kines by AC [24–26], DHA [17] and PI [27], effects that
are generally corroborated in the current study. DHA
appears to be the strongest anti-inflammatory com-
pound among the tested ones as this fatty acid decreased
expression of three out of four investigated pro-
inflammatory cytokines. We also for the first time report
effects of bioactive compounds on chemerin – an insulin
resistance inducing cytokine [8], which is largely se-
creted by adipocytes. DHA was the only compound sup-
pressing chemerin secretion, which was antagonized by
AC. Admittedly, at present we do not know how the se-
lected bioactives regulate adipokine secretion, a question
which needs further investigations. The outcome of
Fig. 4 No effects of bioactives or metabolites on lipid accumulation.
Representative pictures of neutral lipid accumulation (green) and
cell nuclei (blue) staining after 6 days of treatment with bioactive
components (a). Quantified lipid accumulation adjusted for cell
amount (control, n = 8; 0.5 μM DHA, n = 8; AC alone and with DHA,
n = 4; 100 μM PI alone and with DHA, n = 6 biological/independent
experiment in duplicates (b). Normalized data is presented as
means +/- standard deviation versus control. The absence of
statistical significance was determined by the non-parametric
Kruskal-Wallis test
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compound interaction could also depend on their con-
centrations, the effects might not be linear and add-
itional experiments using a concentration-dependent
response for each bioactive alone and in combination
are warranted to better establish any possible additive/
synergistic effects on human adipocytes. However, our
data suggest interactions between bioactives on fat cell
function, which is relevant for in vivo physiology and
nutrition.
Publications from murine 3T3-F442A and -L1 fat cells
as well as isolated primary human adipocytes have dem-
onstrated increased adiponectin secretion after DHA
treatment [18, 19, 53]. However, it should be noted that
fetal bovine serum, an additive which may protect the
cells from ROS exposure, was included in the cell cul-
ture medium in all these previous studies. This may ex-
plain why higher concentrations of DHA could be used
in those experiments. Other possible reasons for the dis-
crepancies may be treatment duration or delivery as in
vitro cell systems seem to be sensitive to this compound.
The effect of PI on adiponectin secretion was unex-
pected, but could be due to its effect on PPARγ reported
previously [54]. On the other hand we did not observe
any effects of the compounds on fat cell differentiation/
lipid accumulation, which speaks against their possible
role regulating important adipogenic factors at least in
in vitro cell system.
Conclusions
Our systematic assessment of DHA, AC and PI, either
alone or in combination with DHA, indicate a beneficial
role on human fat cell function. The selected com-
pounds decreased basal lipolytic activity and secretion of
inflammatory markers in human fat cells which might
explain some of the reported health benefits induced by
bioactive compound-containing diets in humans, includ-
ing reduced insulin resistance, hypertension and dyslip-
idemia [21, 42, 55]. To further elucidate this question,
our in vitro results will be used to identify specific bio-
markers to be measured in volunteers recruited in a
clinical intervention study within the PATHWAY-27
project.
Additional files
Additional file 1: Figure S1. No effect of BSA and EtOH on glycerol
release or IL-6 secretion. Glycerol release (a) and IL-6 secretion (b) after
48 h of treatment with 0.05 % Ethanol (EtOH) and 0.125 μM bovine
serum albumin (BSA) relative to untreated cells in conditioned media
(n = 2 biological/independent experiments in quintuplicates). Normalized
data is adjusted for protein amount and presented as means +/- standard
deviation. The absence of statistical significance was determined by
Tukey’s test. (PPTX 46 kb)
Additional file 2: Figure S2. Adverse effects of DHA on adipocyte
cytotoxicity and IL-6 secretion. Cytotoxicity detection measured as
lactate dehydrogenase (LDH) activity in conditioned media after
6 days of treatment with 0.5 μM, 10 μM or 60 μM DHA, relative to
control (a). Control, n = 7; 0.5 μM DHA, n = 3; 10 μM and 60 μM DHA,
n = 2 biological/independent experiments in at least duplicates. Secretion of
IL-6 from human in vitro differentiated adipocytes after 48 h of treatment
with 0.5 μM, 5 μM, 10 μM, 20 μM, 30 μM or 60 μM DHA compared
to control (b). Control, n = 2 and DHA n = 1 biological/independent
experiments in triplicates. Normalized data is adjusted for protein
amount and presented as means +/- standard deviation. *p < 0.05,
**p < 0.01 and ***p < 0.001 versus control. Statistical significance was
obtained by one-way ANOVA with Tukey’s multiple comparisons post
hoc test. (PPTX 47 kb)
Additional file 3: Figure S3. Decreased cytotoxicity after treatment
with bioactive compounds or metabolites. Lactate dehydrogenase (LDH)
activity after 48 h or 6 days treatment with bioactive compounds relative
to control in conditioned media. Forty-eight hours; control, n = 9; 0.5 μM
DHA, n = 6; AC alone and with DHA, n = 3; 100 μM PI alone and with
DHA, n = 4 biological/independent experiments in quadruplicates; 6 days;
control, n = 7; 0.5 μM DHA, n = 7; AC alone and with DHA, n = 4; 100 μM
PI alone and with DHA, n = 5 biological/independent experiments in
duplicates. Normalized data is adjusted for protein amount in each well
as a measure of cell amount and presented as means +/- standard
deviation. *p < 0.05, **p < 0.01 and ***p < 0.001 versus control. Statistical
significance was determined by one-way ANOVA with Tukey’s multiple
comparisons post hoc test. (PPTX 44 kb)
Abbreviations
AC: anthocyanin; BG: beta-glucan; BMI: body mass index; BSA: bovine serum
albumin; C3G: cyanidin-3-glucoside; CPM: counts per minute;
DHA: docosahexaenoic acid; ELISA: enzyme-linked immunosorbent assay;
LDH: lactate dehydrogenase; IL-6: interleukin-6; MCP-1/ CCL2: monocyte
chemoattractant protein-1; PCA: protocatechuic acid; PI: propionic acid;
PFA: paraformaldehyde solution; PBS: phosphate-buffered saline;
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma; SCFA: short-
chain fatty acid; SDS: sodium dodecyl sulfate; SGBS: Simpson-Golabi-
Behmel syndrome; TAG: triacylglycerol; TNFα: tumour necrosis factor-
alpha; WAT: white adipose tissue.
Competing interests
The authors declare that they have no conflict of interests.
Authors’ contributions
Conception and design (CB, SM, AB, MR, PA, JL); acquisition, analysis and
interpretation of data (all co-authors), drafting the article (CB, UW, MR, PA,
JL); critical revising of the manuscript and final approval of the version to be
published (all co-authors).
Acknowledgements
The research leading to these results has received funding from the
European Union Seventh Framework Programme (FP7/2007-2013) under
grant agreement n° 311876: Pathway-27, the Swedish Research Council and
Karolinska Institutet. We thank Stefan Storcksdieck, Caroline Orfila and
Samantha Sutulic from the PATHWAY-27 consortium (www.pathway27.eu)
for assisting with preparation of the manuscript. The excellent technical
assistance of Gaby Åström, Elisabeth Dungner and Kerstin Wåhlen is
greatly appreciated.
Author details
1Lipid Laboratory, Department of Medicine, Karolinska Institutet, Huddinge,
Stockholm, Sweden. 2Department of Biochemistry and Molecular Biology,
University of Southern Denmark, 5230 Odense M, Denmark. 3Department of
Agro-Food Sciences and Technologies, University of Bologna, Bologna, Italy.
4Department of Plastic Surgery, Akademikliniken, Stockholm, Sweden.
5Department of Medicine, Karolinska Institutet, Lipid Laboratory, Novum, NVS
D4, Hälsovägen 7, 14186 Stockholm, Sweden.
Received: 13 August 2015 Accepted: 14 January 2016
Björk et al. Nutrition & Metabolism  (2016) 13:4 Page 8 of 10
References
1. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation
and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.
2. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids,
and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal
proliferator-activated receptor agonists provide a rational therapeutic
approach. J Clin Endocrinol Metab. 2004;89:463–78.
3. Hoffstedt J, Forster D, Lofgren P. Impaired subcutaneous adipocyte
lipogenesis is associated with systemic insulin resistance and increased
apolipoprotein B/AI ratio in men and women. J Intern Med. 2007;262:131–9.
4. Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia, and obesity-
induced insulin resistance. Trends Endocrinol Metab. 2014;25:255–62.
5. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1
is produced in isolated adipocytes, associated with adiposity and
reduced after weight loss in morbid obese subjects. Int J Obes (Lond).
2005;29:146–50.
6. Dahlman I, Kaaman M, Olsson T, Tan GD, Bickerton AS, Wahlen K, et al.
A unique role of monocyte chemoattractant protein 1 among
chemokines in adipose tissue of obese subjects. J Clin Endocrinol
Metab. 2005;90:5834–40.
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW.
Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest. 2003;112:1796–808.
8. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al.
Chemerin is a novel adipokine associated with obesity and metabolic
syndrome. Endocrinology. 2007;148:4687–94.
9. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose
tissues of obese subjects release interleukin-6: depot difference and
regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–50.
10. Sewter CP, Digby JE, Blows F, Prins J, O'Rahilly S. Regulation of tumour
necrosis factor-alpha release from human adipose tissue in vitro.
J Endocrinol. 1999;163:33–8.
11. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of
metabolic syndrome: Report of the National Heart, Lung, and Blood
Institute/American Heart Association conference on scientific issues related
to definition. Circulation. 2004;109:433–8.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al.
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.
Biochem Biophys Res Commun. 1999;257:79–83.
13. Hoffstedt J, Arvidsson E, Sjolin E, Wahlen K, Arner P. Adipose tissue
adiponectin production and adiponectin serum concentration in human
obesity and insulin resistance. J Clin Endocrinol Metab. 2004;89:1391–6.
14. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of
type 2 diabetes: a systematic review and meta-analysis. JAMA.
2009;302:179–88.
15. Siriwardhana N, Kalupahana NS, Cekanova M, LeMieux M, Greer B,
Moustaid-Moussa N. Modulation of adipose tissue inflammation by
bioactive food compounds. J Nutr Biochem. 2013;24:613–23.
16. Rosa FT, Zulet MA, Marchini JS, Martinez JA. Bioactive compounds with
effects on inflammation markers in humans. Int J Food Sci Nutr.
2012;63:749–65.
17. Murumalla RK, Gunasekaran MK, Padhan JK, Bencharif K, Gence L, Festy F,
et al. Fatty acids do not pay the toll: effect of SFA and PUFA on human
adipose tissue and mature adipocytes inflammation. Lipids Health Dis.
2012;11:175.
18. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, et al.
Adiponectin translation is increased by the PPARgamma agonists
pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab.
2009;296:E480–489.
19. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone
increase adiponectin in an additive and PPARgamma-dependent manner in
human adipocytes. Obesity (Silver Spring). 2011;19:262–8.
20. Warnke I, Goralczyk R, Fuhrer E, Schwager J. Dietary constituents reduce
lipid accumulation in murine C3H10 T1/2 adipocytes: A novel fluorescent
method to quantify fat droplets. Nutr Metab (Lond). 2011;8:30.
21. He J, Giusti MM. Anthocyanins: natural colorants with health-promoting
properties. Annu Rev Food Sci Technol. 2010;1:163–87.
22. Scazzocchio B, Vari R, Filesi C, D'Archivio M, Santangelo C, Giovannini C,
et al. Cyanidin-3-O-beta-glucoside and protocatechuic acid exert insulin-like
effects by upregulating PPARgamma activity in human omental adipocytes.
Diabetes. 2011;60:2234–44.
23. Scazzocchio B, Vari R, Filesi C, Del Gaudio I, D'Archivio M, Santangelo C,
et al. Protocatechuic acid activates key components of insulin signaling
pathway mimicking insulin activity. Mol Nutr Food Res. 2015;59:1472–81.
24. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside
attenuates obesity-associated insulin resistance and hepatic steatosis in
high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr
Biochem. 2012;23:349–60.
25. Sasaki R, Nishimura N, Hoshino H, Isa Y, Kadowaki M, Ichi T, et al. Cyanidin
3-glucoside ameliorates hyperglycemia and insulin sensitivity due to
downregulation of retinol binding protein 4 expression in diabetic mice.
Biochem Pharmacol. 2007;74:1619–27.
26. Tsuda T, Ueno Y, Yoshikawa T, Kojo H, Osawa T. Microarray profiling of gene
expression in human adipocytes in response to anthocyanins. Biochem
Pharmacol. 2006;71:1184–97.
27. Al-Lahham S, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R, et al.
Propionic acid affects immune status and metabolism in adipose tissue
from overweight subjects. Eur J Clin Invest. 2012;42:357–64.
28. Al-Lahham SH, Roelofsen H, Priebe M, Weening D, Dijkstra M, Hoek A, et al.
Regulation of adipokine production in human adipose tissue by propionic
acid. Eur J Clin Invest. 2010;40:401–7.
29. Ge H, Li X, Weiszmann J, Wang P, Baribault H, Chen JL, et al. Activation of G
protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis
and suppression of plasma free fatty acids. Endocrinology. 2008;149:4519–26.
30. Han JH, Kim IS, Jung SH, Lee SG, Son HY, Myung CS. The effects of
propionate and valerate on insulin responsiveness for glucose uptake in
3 T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41.
PLoS One. 2014;9:e95268.
31. Heimann E, Nymann M, Degerman E. Propionic acid and butyric acid inhibit
lipolysis and de novo lipogenesis and increase insulin-stimulated glucose
uptake in primary rat adipocytes. Adipocyte. 2014;4:1–8.
32. Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, et al.
Acetate and propionate short chain fatty acids stimulate adipogenesis via
GPCR43. Endocrinology. 2005;146:5092–9.
33. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role.
Best Pract Res Clin Endocrinol Metab. 2005;19:471–82.
34. Mikkelsen TS, Xu Z, Zhang X, Wang L, Gimble JM, Lander ES, et al.
Comparative epigenomic analysis of murine and human adipogenesis.
Cell. 2010;143:156–69.
35. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell.
2014;156:20–44.
36. van Harmelen V, Skurk T, Hauner H. Primary culture and differentiation of
human adipocyte precursor cells. Methods Mol Med. 2005;107:125–35.
37. Wang YC, Kuo WH, Chen CY, Lin HY, Wu HT, Liu BH, et al. Docosahexaenoic
acid regulates serum amyloid A protein to promote lipolysis through down
regulation of perilipin. J Nutr Biochem. 2010;21:317–24.
38. Schlesinger JB, van Harmelen V, Alberti-Huber CE, Hauner H. Albumin
inhibits adipogenesis and stimulates cytokine release from human
adipocytes. Am J Physiol Cell Physiol. 2006;291:C27–33.
39. Hellmer J, Arner P, Lundin A. Automatic luminometric kinetic assay of
glycerol for lipolysis studies. Anal Biochem. 1989;177:132–7.
40. Stenson BM, Ryden M, Venteclef N, Dahlman I, Pettersson AM, Mairal A,
et al. Liver X receptor (LXR) regulates human adipocyte lipolysis. J Biol
Chem. 2011;286:370–9.
41. Murali G, Desouza CV, Clevenger ME, Ramalingam R, Saraswathi V.
Differential effects of eicosapentaenoic acid and docosahexaenoic acid in
promoting the differentiation of 3 T3-L1 preadipocytes. Prostaglandins
Leukot Essent Fatty Acids. 2014;90:13–21.
42. Lorente-Cebrian S, Costa AG, Navas-Carretero S, Zabala M, Martinez JA,
Moreno-Aliaga MJ. Role of omega-3 fatty acids in obesity, metabolic
syndrome, and cardiovascular diseases: a review of the evidence. J Physiol
Biochem. 2013;69:633–51.
43. Attar-Bashi NM, Weisinger RS, Begg DP, Li D, Sinclair AJ. Failure of
conjugated linoleic acid supplementation to enhance biosynthesis of
docosahexaenoic acid from alpha-linolenic acid in healthy human
volunteers. Prostaglandins Leukot Essent Fatty Acids. 2007;76:121–30.
44. Pawlosky RJ, Hibbeln JR, Herion D, Kleiner DE, Salem Jr N. Compartmental
analysis of plasma and liver n-3 essential fatty acids in alcohol-dependent
men during withdrawal. J Lipid Res. 2009;50:154–61.
45. Kim HK, Della-Fera M, Lin J, Baile CA. Docosahexaenoic acid inhibits
adipocyte differentiation and induces apoptosis in 3 T3-L1 preadipocytes.
J Nutr. 2006;136:2965–9.
Björk et al. Nutrition & Metabolism  (2016) 13:4 Page 9 of 10
46. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate
immunity and fatty acid-induced insulin resistance. J Clin Invest.
2006;116:3015–25.
47. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis
factor-alpha suppresses adipocyte-specific genes and activates expression of
preadipocyte genes in 3 T3-L1 adipocytes: nuclear factor-kappaB activation
by TNF-alpha is obligatory. Diabetes. 2002;51:1319–36.
48. Czank C, Cassidy A, Zhang Q, Morrison DJ, Preston T, Kroon PA, et al.
Human metabolism and elimination of the anthocyanin, cyanidin-3-
glucoside: a (13)C-tracer study. Am J Clin Nutr. 2013;97:995–1003.
49. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing
effects of dietary resistant starch and effects on skeletal muscle and adipose
tissue metabolism. Am J Clin Nutr. 2005;82:559–67.
50. Guo H, Guo J, Jiang X, Li Z, Ling W. Cyanidin-3-O-beta-glucoside, a typical
anthocyanin, exhibits antilipolytic effects in 3 T3-L1 adipocytes during
hyperglycemia: involvement of FoxO1-mediated transcription of adipose
triglyceride lipase. Food Chem Toxicol. 2012;50:3040–7.
51. Chuang CC, Bumrungpert A, Kennedy A, Overman A, West T, Dawson B,
et al. Grape powder extract attenuates tumor necrosis factor alpha-
mediated inflammation and insulin resistance in primary cultures of human
adipocytes. J Nutr Biochem. 2011;22:89–94.
52. Pettersson AM, Acosta JR, Bjork C, Kratzel J, Stenson B, Blomqvist L, et al.
MAFB as a novel regulator of human adipose tissue inflammation.
Diabetologia. 2015;58:2115–23.
53. Oster RT, Tishinsky JM, Yuan Z, Robinson LE. Docosahexaenoic acid
increases cellular adiponectin mRNA and secreted adiponectin protein, as
well as PPARgamma mRNA, in 3 T3-L1 adipocytes. Appl Physiol Nutr Metab.
2010;35:783–9.
54. Besten GD, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, et al.
Short-chain fatty acids protect against high-fat diet-induced obesity via a
PPARgamma-dependent switch from lipogenesis to fat oxidation. Diabetes.
2015;64:2398–408.
55. El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits
in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Björk et al. Nutrition & Metabolism  (2016) 13:4 Page 10 of 10
